Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sodium thiosulfate - Fennec Pharmaceuticals

Drug Profile

Sodium thiosulfate - Fennec Pharmaceuticals

Alternative Names: PEDMARK; sodium-hyposulfite; STS - Fennec

Latest Information Update: 25 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oregon Health & Science University
  • Developer Fennec Pharmaceuticals
  • Class Antidotes; Antituberculars; Chemoprotectants; Thiosulfates; Vasodilators
  • Mechanism of Action Antioxidants; Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sensorineural hearing loss
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Sensorineural hearing loss

Most Recent Events

  • 21 Oct 2019 Fennec Pharmaceuticals initiates an expanded-access programme for Sensorineural hearing loss in Turkey (NCT04132882)
  • 09 Aug 2019 Fennec Pharmaceutical anticipates the completion of the rolling NDA filing for Sodium thiosulfate by early 2020
  • 09 Aug 2019 Fennec Pharmaceuticals intends to launch Sodium thiosulfate in the second half of 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top